Good Half yearly.
It reminds me that the company does have revenue derived from its partnership with GE Healthcare.
I like the way the company reports its results and separates what is revenue and what is Research Tax Incentive. Other billion dollar companies are not so accurate and you can get misleading headlines like:
Imugene (ASX:IMU) generates income of $5.34m in H1 FY22
on the same day, where there was zero income from sales. I don't recall anyone's research incentive being the subject of a headline before.
Ultimately you invest in the company you trust, and where you can point to an independent, profitable company buying their IP.
